BACKGROUND: Meningeal hemangiopericytoma (M-HPC) is a rare entity.
OBJECTIVE: To characterize our institutional experience in treating M-HPC.
METHODS: We reviewed the medical records of patients with M-HPC evaluated at The University of Texas M.D. Anderson Cancer Center between 1979 and 2009.
RESULTS: We identified 63 patients diagnosed between 1979 and 2009 with M-HPC treated with surgery alone or with postoperative radiotherapy (PORT). The majority were male (59%) and with a median age of 40.9 years (range, 0-71). Gross total resection (GTR) predominated (n = 31, 49%) followed by subtotal resection (n = 23, 37%) and unknown status (n = 9, 14.3%). PORT was delivered to 39 of the 63 patients (62%). The 5-, 10-, and 15-year overall survival were 90%, 68%, and 28%, respectively. The 5-, 10-, and 15-year local control (LC) were 70%, 37%, and 20%, respectively. The 5-, 10-, and 15-year metastasis-free survival were 85%, 39%, and 7%. PORT resulted in improved LC (hazard ratio [HR] 0.38, P = .008). Radiotherapy (RT) dose ≥60 Gy correlated with improved LC relative to <60 Gy (HR 0.12, P = .045). GTR correlated with improved LC (HR 0.40, P = .03). On multivariate analysis, PORT (HR 0.33, P = .003), GTR (HR = 0.33, P = .008), and RT dose ≥60 Gy (HR 0.33, P = .003) correlated with improved LC. Among those with GTR, PORT resulted in improved LC (HR 0.18, P = .027). Extent of resection and PORT did not correlate with improved overall survival.
CONCLUSION: In M-HPC, both PORT and GTR independently correlate with improved LC. PORT improves LC following GTR. We recommend RT dose ≥60 Gy to optimize LC.
ABBREVIATIONS: BED, biologically equivalent dose
CSS, cause-specific survival
LC, local control
MFS, metastasis-free survival
M-HPC, meningeal hemangiopericytoma
MVA, multivariate analysis
OS, overall survival
PORT, postoperative radiotherapy
RFS, recurrence-free survival
STR, subtotal resection
*Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;
‡Department of Radiation Oncology, The University of Southern California, Los Angeles, California;
§Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;
‖Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
Correspondence: Amol J. Ghia, 1515 Holcombe Blvd, Unit 0097, Houston, TX 77030. E-mail: email@example.com
Received December 21, 2012
Accepted June 20, 2013